ERE-independent ERα target genes differentially expressed in human breast tumors

Christine Glidewell-Kenney, Jeffrey Weiss, Eun Jig Lee, Suresh Pillai, Toshio Ishikawa, Eric A. Ariazi, J. Larry Jameson

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The classical pathway for estrogen receptor (ER) signaling is mediated by ER binding to an estrogen response element (ERE) in DNA. ERα can also act via a nonclassical pathway by altering the activities of other transcription factors (e.g., Sp1, AP-1, or NF-κB) at their cognate sites on DNA. We previously generated a mutant form of ERα (E207A/G208A) that does not bind to EREs, and therefore lacks signaling via the classical pathway but retains signaling via the nonclassical pathway. In the current study, we introduce this mutant ERα into MDA-MB231 ERα-negative breast carcinoma cells to identify nonclassical pathway genes that respond to 17β-estradiol (E2), selective estrogen receptor modulators (SERMs) tamoxifen (TAM) or raloxifene (RAL), or the estrogen antagonist ICI 182,780 (ICI). Consistent with a role for nonclassical signaling in SERM action, microarray analyses identify 268 responsive nonclassical ERα pathway target genes. ICI elicits the largest number of nonclassical genes, followed by RAL, TAM, and E2. Custom microarrays containing identified nonclassical ERα responsive genes are used to compare gene expression in human breast tumor (n = 34) and normal mammary epithelial cell (n = 9) samples. A subset of nonclassical genes (n = 32) are differentially expressed in breast tumors. In summary, we show that nonclassical ERα pathway target genes exhibit a range of transcriptional responses to SERMs and identify targets of this pathway as potentially relevant to breast cancer. The identification of nonclassical ERα target genes offers new insight into estrogen receptor signaling and cross talk with pathways that mediate breast tumor response to SERM therapy.

Original languageEnglish
Pages (from-to)53-59
Number of pages7
JournalMolecular and Cellular Endocrinology
Volume245
Issue number1-2
DOIs
Publication statusPublished - 2005 Dec 21

Fingerprint

Response Elements
Estrogen Receptors
Tumors
Estrogens
Genes
Breast Neoplasms
Selective Estrogen Receptor Modulators
Tamoxifen
Microarrays
Receptor Cross-Talk
Sp1 Transcription Factor
Estrogen Antagonists
DNA
Transcription Factor AP-1
Microarray Analysis
Gene expression
Estradiol
Breast
Transcription Factors
Epithelial Cells

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Endocrinology

Cite this

Glidewell-Kenney, C., Weiss, J., Lee, E. J., Pillai, S., Ishikawa, T., Ariazi, E. A., & Jameson, J. L. (2005). ERE-independent ERα target genes differentially expressed in human breast tumors. Molecular and Cellular Endocrinology, 245(1-2), 53-59. https://doi.org/10.1016/j.mce.2005.10.003
Glidewell-Kenney, Christine ; Weiss, Jeffrey ; Lee, Eun Jig ; Pillai, Suresh ; Ishikawa, Toshio ; Ariazi, Eric A. ; Jameson, J. Larry. / ERE-independent ERα target genes differentially expressed in human breast tumors. In: Molecular and Cellular Endocrinology. 2005 ; Vol. 245, No. 1-2. pp. 53-59.
@article{e4076a74bb824596987e8e3b37236033,
title = "ERE-independent ERα target genes differentially expressed in human breast tumors",
abstract = "The classical pathway for estrogen receptor (ER) signaling is mediated by ER binding to an estrogen response element (ERE) in DNA. ERα can also act via a nonclassical pathway by altering the activities of other transcription factors (e.g., Sp1, AP-1, or NF-κB) at their cognate sites on DNA. We previously generated a mutant form of ERα (E207A/G208A) that does not bind to EREs, and therefore lacks signaling via the classical pathway but retains signaling via the nonclassical pathway. In the current study, we introduce this mutant ERα into MDA-MB231 ERα-negative breast carcinoma cells to identify nonclassical pathway genes that respond to 17β-estradiol (E2), selective estrogen receptor modulators (SERMs) tamoxifen (TAM) or raloxifene (RAL), or the estrogen antagonist ICI 182,780 (ICI). Consistent with a role for nonclassical signaling in SERM action, microarray analyses identify 268 responsive nonclassical ERα pathway target genes. ICI elicits the largest number of nonclassical genes, followed by RAL, TAM, and E2. Custom microarrays containing identified nonclassical ERα responsive genes are used to compare gene expression in human breast tumor (n = 34) and normal mammary epithelial cell (n = 9) samples. A subset of nonclassical genes (n = 32) are differentially expressed in breast tumors. In summary, we show that nonclassical ERα pathway target genes exhibit a range of transcriptional responses to SERMs and identify targets of this pathway as potentially relevant to breast cancer. The identification of nonclassical ERα target genes offers new insight into estrogen receptor signaling and cross talk with pathways that mediate breast tumor response to SERM therapy.",
author = "Christine Glidewell-Kenney and Jeffrey Weiss and Lee, {Eun Jig} and Suresh Pillai and Toshio Ishikawa and Ariazi, {Eric A.} and Jameson, {J. Larry}",
year = "2005",
month = "12",
day = "21",
doi = "10.1016/j.mce.2005.10.003",
language = "English",
volume = "245",
pages = "53--59",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

Glidewell-Kenney, C, Weiss, J, Lee, EJ, Pillai, S, Ishikawa, T, Ariazi, EA & Jameson, JL 2005, 'ERE-independent ERα target genes differentially expressed in human breast tumors', Molecular and Cellular Endocrinology, vol. 245, no. 1-2, pp. 53-59. https://doi.org/10.1016/j.mce.2005.10.003

ERE-independent ERα target genes differentially expressed in human breast tumors. / Glidewell-Kenney, Christine; Weiss, Jeffrey; Lee, Eun Jig; Pillai, Suresh; Ishikawa, Toshio; Ariazi, Eric A.; Jameson, J. Larry.

In: Molecular and Cellular Endocrinology, Vol. 245, No. 1-2, 21.12.2005, p. 53-59.

Research output: Contribution to journalArticle

TY - JOUR

T1 - ERE-independent ERα target genes differentially expressed in human breast tumors

AU - Glidewell-Kenney, Christine

AU - Weiss, Jeffrey

AU - Lee, Eun Jig

AU - Pillai, Suresh

AU - Ishikawa, Toshio

AU - Ariazi, Eric A.

AU - Jameson, J. Larry

PY - 2005/12/21

Y1 - 2005/12/21

N2 - The classical pathway for estrogen receptor (ER) signaling is mediated by ER binding to an estrogen response element (ERE) in DNA. ERα can also act via a nonclassical pathway by altering the activities of other transcription factors (e.g., Sp1, AP-1, or NF-κB) at their cognate sites on DNA. We previously generated a mutant form of ERα (E207A/G208A) that does not bind to EREs, and therefore lacks signaling via the classical pathway but retains signaling via the nonclassical pathway. In the current study, we introduce this mutant ERα into MDA-MB231 ERα-negative breast carcinoma cells to identify nonclassical pathway genes that respond to 17β-estradiol (E2), selective estrogen receptor modulators (SERMs) tamoxifen (TAM) or raloxifene (RAL), or the estrogen antagonist ICI 182,780 (ICI). Consistent with a role for nonclassical signaling in SERM action, microarray analyses identify 268 responsive nonclassical ERα pathway target genes. ICI elicits the largest number of nonclassical genes, followed by RAL, TAM, and E2. Custom microarrays containing identified nonclassical ERα responsive genes are used to compare gene expression in human breast tumor (n = 34) and normal mammary epithelial cell (n = 9) samples. A subset of nonclassical genes (n = 32) are differentially expressed in breast tumors. In summary, we show that nonclassical ERα pathway target genes exhibit a range of transcriptional responses to SERMs and identify targets of this pathway as potentially relevant to breast cancer. The identification of nonclassical ERα target genes offers new insight into estrogen receptor signaling and cross talk with pathways that mediate breast tumor response to SERM therapy.

AB - The classical pathway for estrogen receptor (ER) signaling is mediated by ER binding to an estrogen response element (ERE) in DNA. ERα can also act via a nonclassical pathway by altering the activities of other transcription factors (e.g., Sp1, AP-1, or NF-κB) at their cognate sites on DNA. We previously generated a mutant form of ERα (E207A/G208A) that does not bind to EREs, and therefore lacks signaling via the classical pathway but retains signaling via the nonclassical pathway. In the current study, we introduce this mutant ERα into MDA-MB231 ERα-negative breast carcinoma cells to identify nonclassical pathway genes that respond to 17β-estradiol (E2), selective estrogen receptor modulators (SERMs) tamoxifen (TAM) or raloxifene (RAL), or the estrogen antagonist ICI 182,780 (ICI). Consistent with a role for nonclassical signaling in SERM action, microarray analyses identify 268 responsive nonclassical ERα pathway target genes. ICI elicits the largest number of nonclassical genes, followed by RAL, TAM, and E2. Custom microarrays containing identified nonclassical ERα responsive genes are used to compare gene expression in human breast tumor (n = 34) and normal mammary epithelial cell (n = 9) samples. A subset of nonclassical genes (n = 32) are differentially expressed in breast tumors. In summary, we show that nonclassical ERα pathway target genes exhibit a range of transcriptional responses to SERMs and identify targets of this pathway as potentially relevant to breast cancer. The identification of nonclassical ERα target genes offers new insight into estrogen receptor signaling and cross talk with pathways that mediate breast tumor response to SERM therapy.

UR - http://www.scopus.com/inward/record.url?scp=30044439766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30044439766&partnerID=8YFLogxK

U2 - 10.1016/j.mce.2005.10.003

DO - 10.1016/j.mce.2005.10.003

M3 - Article

C2 - 16298037

AN - SCOPUS:30044439766

VL - 245

SP - 53

EP - 59

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

IS - 1-2

ER -